Florida Cancer Specialists-Panhandle

Tallahassee, Florida 32308

0 studies enrolling now · 11 studies all time

What they study most

Advanced Solid Tumor, Androgen-Resistant Prostatic Neoplasms, Cancer, Castration Resistant Prostatic Neoplasms, Chemotherapeutic Toxicity, Colorectal Cancer, Colorectal Cancer Metastatic, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Lung Cancer

Studies at this site

• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) — Completed
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. — Running, not enrolling
• HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer — Running, not enrolling
• Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer — Completed
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor — Completed
• Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer — Completed
• A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors — Stopped early
• StrataPATH™ (Precision Indications for Approved Therapies) — Stopped early
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): — Stopped early
• A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression — Completed